Detalhe da pesquisa
1.
Recurrent heart failure hospitalizations increase the risk of mortality in heart failure patients with atrial fibrillation and type 2 diabetes mellitus in the United Kingdom: a retrospective analysis of Clinical Practice Research Datalink database.
BMC Cardiovasc Disord
; 22(1): 234, 2022 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35597922
2.
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
Eur J Heart Fail
; 26(3): 628-637, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38450878
3.
Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study.
Cardiol Ther
; 11(1): 113-127, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35094306
4.
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review.
Int J Cardiol
; 331: 164-171, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545266
5.
Caregivers of Patients with Heart Failure: Burden and the Determinants of Health-Related Quality of Life.
Patient Prefer Adherence
; 15: 1153-1164, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34079236
6.
Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study.
Patient Prefer Adherence
; 15: 1693-1706, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34354345
7.
Recurrent heart failure hospitalizations increase the risk of cardiovascular and all-cause mortality in patients with heart failure in Sweden: a real-world study.
ESC Heart Fail
; 8(3): 2144-2153, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751806
8.
Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink.
ESC Heart Fail
; 7(4): 1688-1699, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383551
9.
Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure.
ESC Heart Fail
; 7(5): 2406-2417, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32667143
10.
Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).
Crit Care Med
; 36(9): 2576-82, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18679128
11.
A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA.
Am J Cardiovasc Drugs
; 18(3): 205-211, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29177815
12.
The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
Diabetes
; 55(1): 110-9, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16380483
13.
Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization.
Arterioscler Thromb Vasc Biol
; 26(3): 488-93, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16385086
14.
The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
Circulation
; 112(19): 3001-8, 2005 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-16260636
15.
Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study.
Eur Heart J
; 26(15): 1557-61, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15734766